Available to mentor
William H. Herman is the Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes, Professor of Internal Medicine in the Division of Metabolism, Endocrinology, and Diabetes and Professor of Epidemiology in the School of Public Health. He completed his undergraduate degree at Yale University and received his medical degree from Boston University. He gained a Masters of Public Health (Epidemiology) from the University of Michigan. Professor Herman's interests include clinical diabetes and diabetes epidemiology, especially in the areas of surveillance, screening, treatment, cost-effective analysis, and health policy. He has authored more than 400 original research papers, reviews and textbook chapters and is U-M Principal Investigator for the Diabetes Control and Complications Trial (DCCT), Epidemiology of Diabetes Interventions and Complications (EDIC), Diabetes Prevention Program (DPP), Diabetes Prevention Program Outcomes Study (DPPOS), and The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Professor Herman received the American Diabetes Association's Kelly West Award for outstanding achievement in diabetes epidemiology in 2006 and the U-M Dean's Award for Clinical and Health Services Research in 2007. From 2018 to 2021, he chaired the National Clinical Care Commission, a federal advisory committee charged with advising the Congress how to leverage federal policies and programs to better prevent and control diabetes in the United States. He has been recognized by Best Doctors as a Best Doctor in America for more than 10 years.
-
Center MemberCaswell Diabetes Institute
-
Center MemberGlobal REACH
-
Center MemberInstitute for Healthcare Policy and Innovation
-
Nathan DM, Herman WH, Larkin ME, Krause-Steinrauf H, Abou Assi H, Ahmann AJ, Brown-Friday J, Hsia DS, Harindhanavudhi T, Johnson M, Arends VL, Butera NM, Rosin SP, Lachin JM, Younes N, GRADE Study Research Group . Diabetes Care, 2024 Dec 1; 47 (12): 2155 - 2163.Journal ArticleRelationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial.
DOI:10.2337/dc24-1362 PMID: 39312277 -
Kuo S, Ye W, Wang D, McEwen LN, Villatoro Santos C, Herman WH. Diabetes Care, 2024 Nov 20;Journal ArticleCost-Effectiveness of the National Diabetes Prevention Program: A Real-World, 2-Year Prospective Study.
DOI:10.2337/dc24-1110 PMID: 39565893 -
Grant-Alfieri A, Herman WH, Watkins DJ, Batterman S, Karvonen-Gutierrez C, Park SK. Environ Res, 2024 Nov 1; 260: 119582Journal ArticleAssociations of serum persistent organic pollutant concentrations with incident diabetes in midlife women: The Study of Women's Health Across the Nation Multi-Pollutant Study.
DOI:10.1016/j.envres.2024.119582 PMID: 38992756 -
Schmittdiel JA, Herman WH, Thornton P, Pragnell M, Haire-Joshu D. J Clin Transl Sci, 2024 8 (1): e131Journal ArticleAdapting the Translational Science Benefits Model to improve health and advance health equity in diabetes: The Centers for Diabetes Translation Research Impact Framework.
DOI:10.1017/cts.2024.580 PMID: 39345691 -
Braffett BH, El Ghormli L, Albers JW, Feldman EL, Herman WH, Gubitosi-Klug RA, Martin CL, Orchard TJ, White NH, Lachin JM, Perkins BA, Pop-Busui R, DCCT/EDIC Research Group . Diabetes Care, 2024 Sep 1; 47 (9): 1559 - 1567.Journal ArticleNeuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes.
DOI:10.2337/dc23-1749 PMID: 38300889 -
Broome DT, Mehdi A, Chase C, de Freitas MF, Gregg BE, Oral EA, Herman WH. Diabetes Care, 2024 Sep 1; 47 (9): e65 - e66.Journal ArticleUse of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY.
DOI:10.2337/dc24-0730 PMID: 39008714 -
Sweeting A, Hannah W, Backman H, Catalano P, Feghali M, Herman WH, Hivert M-F, Immanuel J, Meek C, Oppermann ML, Nolan CJ, Ram U, Schmidt MI, Simmons D, Chivese T, Benhalima K. Lancet, 2024 Jul 13; 404 (10448): 175 - 192.Journal ArticleEpidemiology and management of gestational diabetes.
DOI:10.1016/S0140-6736(24)00825-0 PMID: 38909620 -
Rothberg AE, Herman WH. Nephrol Dial Transplant, 2024 Jun 28; 39 (7): 1060 - 1062.Journal ArticleHow to assess kidney outcomes in obese people with substantial weight loss: the case of GLP1- and dual-receptor agonists.
DOI:10.1093/ndt/gfae024 PMID: 38299776